接受干扰素-利巴韦林治疗患者中VERSANT HCV RNA定性检测（转录介导扩增法）与COBAS AMPLICOR丙型肝炎病毒检测2.0版的比较
Comparison of the VERSANT HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy.
作者信息
Germer Jeffrey J, Zein Nizar N, Metwally Mohamed A, Hoskin Tanya L, Scott Harmsen W, Smith Thomas F, Patel Robin
机构信息
Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, USA.
出版信息
Diagn Microbiol Infect Dis. 2003 Dec;47(4):615-8. doi: 10.1016/s0732-8893(03)00149-4.
Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.
在干扰素-利巴韦林治疗期间的不同时间点，使用两种定性检测方法对丙型肝炎病毒（HCV）感染患者进行HCV RNA检测。在接受48周治疗的患者中，转录介导扩增法和COBAS AMPLICOR丙型肝炎病毒检测法在第24周时的结果分别预测了12/15（80%）和8/15（53%）的患者随后出现病毒学无应答或病毒学复发。
Zotero 插件